Navigation Links
Normal Cells May Predict Cancer Virulence
Date:8/28/2008

Finding suggests that treatment that only aims at malignant cells might fall short

THURSDAY, Aug. 28 (HealthDay News) -- Characteristics of normal cells which are present long before any tumor appears may determine how virulent a particular cancer is going to be, new research suggests.

Such cells may travel early on to distant sites in the body, residing innocently there until certain cancer genes are turned on.

"It's definitely conceptually very profound," said Dr. Katrina Podsypanina, a senior research scientist at Memorial-Sloan Kettering Cancer Center in New York City. "Our data seems to point toward the inherent decision that is made when the tumor is formed whether it is highly malignant or not. Moreover, since the characteristic might be dependent on the normal cell status, one might imagine that they might be different between individuals."

The study's senior author is Harold Varmus, who won the 1989 Nobel Prize for his work in cancer genetics and later went on to become director of the National Institutes of Health.

The finding implies that treatments that only target malignant cells may not be effective.

So far, however, the findings have only been shown in mice, and the research involved certain processes that were imposed which wouldn't normally occur in the human body.

"This does suggest that cells can sit for a long time, then be activated," said Dr. Claudine Isaacs, director of the clinical breast cancer program at Georgetown's Lombardi Comprehensive Cancer Center in Washington, D.C. "But these cells were injected into the circulation. Normal breast cells are not supposed to be in the circulation."

Also, the normal cells didn't form tumors until activated.

Conventional medical wisdom holds that the spread of a cancer occurs relatively late in the life of a cancer, happening only after cells from the primary tumor have undergone enough mutations to switch on different cancer genes.

Podsypanina and her colleagues performed a series of experiments in mice.

First, they injected normal mammary cells that contained cancer-inducing oncogenes, which could be switched on and off. These cells migrated through the bloodstream to the lungs, residing there for four months. They did not begin to grow aggressively until the oncogenes had been turned on, but they did so without first going through the stage of being a primary tumor.

Next, they injected normal cells without manipulating any oncogenes.

"Cells that did not have any oncogenes in them and do not transform spontaneously as per all published studies, we could see little colonies of these cells when we inspected the lungs," Podsypanina said. "At no point, never, did we see a solid vision that would resemble metastatic colonies, [but] it appears that every time we looked at the animal, the colonies appeared to be larger."

When these normal ectopic cells were injected back into a new generation of mice, they developed into normal mammary glands.

"It's a beginning," Podsypanina said. "It's an important step to show whether or not the first step of the metastatic cascade is something a normal cell can accomplish."

More information

Visit the American Cancer Society for more on oncogenes.



SOURCES: Katrina Podsypanina, M.D., Ph.D., senior research scientist, department of cancer biology and genetics, Memorial Sloan-Kettering Cancer Center, New York City; Claudine Isaacs, M.D., director, clinical breast cancer program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.; Aug. 28, 2008, Science


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Clinical depression linked to abnormal emotional brain circuits
2. Brain imaging reveals breakdown of normal emotional processing
3. Normal role for schizophrenia risk gene identified
4. Novadaq Resumes Normal Business Operations by Securing ICG for SPY
5. How Candida albicans transforms from its normally benign form into life-threatening form
6. Grant Supports Study of Abnormal Ring-Shaped Chromosomes
7. How shyness and other normal human traits became sickness
8. Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not
9. Normal tissue not spared in new forms of breast cancer radiotherapy
10. Abnormal immune cells may cause unprovoked anaphylaxis
11. Abnormal glutamine repeats interfere with key transcription factor, leading to neurodegeneration
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Normal Cells May Predict Cancer Virulence
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: